Catalog Advanced Search
Public Health SIG: Population Health Management of CirrhosisContains 4 Component(s) Recorded On: 11/11/2016
AASLD's Public Health SIG presented at The Liver Meeting® 2016.
This program is intended to explore current and novel health care delivery approaches and strategies for managing populations affected by cirrhosis and portal hypertension. In contrast to disease-based symposium focused on novel diagnostic and treatment approaches, this program intends to focus on current and evolving approaches inspired by delivery system reform to ensure that high quality, patient-centered, and resource efficien medical care is delivered to large segments of patients with advanced liver disease. The emphasis of this program is on clinical knowledge.
Brett E. Fortune
Dr. Brett E. Fortune, MD, MSc, is a Transplant Hepatologist who works at New York Presbyterian/Weill Cornell for the Center for Liver Disease and Transplantation. Dr. Fortune has a clinical focus to provide excellent care for patients with advanced liver disease and those who need or have received liver transplantation. His research interests include clinical outcomes related to complications of cirrhosis and portal hypertension as well as quality improvement in the care of patients with cirrhosis or those who have received a liver transplant.
Clinical Research WorkshopContains 3 Component(s) Recorded On: 11/11/2016
AASLD's Clinical Research Workshop presented at The Liver Meeting® 2016.
This program will address the various designs used in patient-oriented research, including the strengths and limitations to each approach as well as the impact each technique has had on the study and care of patients with liver disease. In addition, approaches to obtaining funding for such research, as well as the development and use of quality measures for the care of patients with chronic liver disease will be discussed. Participants will have the opportunity to obtain more "hands-on" experience and direct feedback from experienced investigators during a series of dynamic and interactive breakout sessions.
Zobair M. Younossi
David R. Nelson
New Concepts and Insights Into HBV ImmunologyContains 1 Component(s) Recorded On: 10/11/2016
Webinar hosted by the Hepatitis B Special Interest group on October 11, 2016.
This webinar will review the current state of the understanding of the immune response to hepatitis b (HBV). Two experts and one moderator will guide providers through an understanding of the HBV immune interactions that can help providers understand and help explain HBV infections, guide patient management and help embrace new therapies.
Robert G. Gish (Moderator)
Dr. Robert G. Gish is a Clinical Professor of Medicine at the University of Nevada in Las Vegas and is a senior consultant at St Joseph’s Medical Center in Phoenix as well as Professor Consultant, Stanford University. In 2013, he founded the consulting company Robert G. Gish Consultants, LLC to provide consultative support to Pharma, nonprofits and hepatology centers and liver transplant programs that wish to start or grow their programs through pathways of quality and optimal patient care that is integrated with research and education. Dr. Gish began his medical training in 1974 when he was enrolled in the pharmacy school at the University of Kansas and then transferred to the University of Kansas Medical School in 1977 and finished his Doctor of Medicine degree in 1980. Dr. Gish went on to complete a three year internal medicine residency at the University of California, San Diego and a four-year gastroenterology and hepatology fellowship at the University of California, Los Angeles. Dr. Gish has had and continues to have an active research program in viral hepatitis, liver transplant, bio-artificial liver, and public policy especially related to liver cancer, liver transplantation, and viral hepatitis.
Dr. Antonio Bertoletti is an expert in the field of viral hepatitis, with a specific interest in the immunopathogenesis of HBV infection. He began working in viral hepatitis as a medical student at the University of Parma (Italy). He continued his research work at the Scripps Research Institute (La Jolla) characterizing for the first time the Hepatitis B virus (HBV) specific cytotoxic T cell response in man. He returned to the University of Parma, where he worked in the Department of Infectious Diseases as a Clinical Scientist and then worked at the University College of London (UK) (1997-2006) before moving to Singapore where he is now Professor at the Emerging Viral Disease Program at Duke-NUS Medical School. His current research is focus on the development of new immunological based therapies (TCR-redirected T cells, HLA-peptide specific antibodies) for the treatment of HBV and HBV-related HCC.
Dr. Kyong-Mi Chang is an Associate Professor of Medicine in the Division of Gastroenterology at the University of Pennsylvania Perelman School of Medicine, with administrative leadership role as the Associate Chief of Staff and Associate Dean for Research at the Philadelphia Corporal Michael J. Crescenz VA Medical Center (CMC VAMC). Dr. Chang received her MD and Internal Medicine residency training from the Medical College of Pennsylvania, followed by clinical GI fellowship training at the University of California in San Diego, also receiving her postdoctoral research training at the Scripps Research Institute studying CTL escape in HCV persistence. She has been a faculty member in GI Division at the University of Pennsylvania School of Medicine and the CMC VAMC since 1999 with active clinical and research activities. Her translational research focuses on immune pathogenesis in human hepatitis C and B virus infection with and without HIV coinfection—including various immune regulatory mechanisms such as FoxP3+ Tregs, IL-10+ Tr1 cells, gdT-cells, PD-1 and CTLA-4. Dr. Chang is also participating in the Million Veteran Program—a multi-center VA genomic study. She is a Fellow of the American Association for Study of Liver Disease (FAASLD) and a member of the American Society for Clinical Investigation (ASCI).
Management of Bleeding Fundal and Ectopic Varices – TIPS, BRTO, and EmbolizationContains 1 Component(s) Recorded On: 10/06/2016
Webinar hosted by the Portal Hypertension Special Interest group on October 6, 2016.
The evidence to support therapeutic decisions in patients with cirrhosis and fundal and ectopic varices is scarce, and treatment is controversial. In addition, since these varices are infrequent, clinicians have limited experience and knowledge of the therapeutic options. This webinar is aimed at providing an update on the treatment of patients with cirrhosis who are bleeding from fundal and ectopic varices, by providing the perspective of an expert clinician and an interventional radiologist, both North American leaders in the field.
Guadalupe Garcia-Tsao (Moderator)
Dr. Garcia-Tsao is Professor of Medicine, Chief of Digestive Diseases and Program Director of the Hepatitis C Resource Center at Veteran’s Administration-Connecticut Healthcare System, as well as Director of Clinical and Translational Core at Yale Liver Center. She is a past president of AASLD. She received her M.D. and training at Universidad Nacional Autónoma de Mexico. Her primary research focus is on clinical research which focuses on cirrhosis and its complications, and she also is involved in the study of bacterial infections in cirrhosis, a complication that is often overlooked.
Jonel Trebicka (Moderator)
Dr. Jonel Trebicka is head of the Laboratory for Liver Fibrosis and Portal Hypertension, as well as the TIPS-Outpatient Clinic at the University Hospital Bonn, Germany. He is also an adjunct professor in gastroenterology and hepatology in Odense, Denmark. Dr. Trebicka is a member of the editorial board of American Journal of Physiology: Gastrointestinal and Liver Physiology, Scientific Reports and Journal of Hepatology, as well as in the Steering Committee of VALDIG-Consortium, Baveno-Cooperation and EF-CLIF. He was a faculty member at the BAVENO VI Consensus-Conference.
Thomas D. Boyer
Dr. Thomas D. Boyer is currently Professor of Medicine and Director of the Liver Research Institute at the University of Arizona School of Medicine in Tucson, Arizona. He has a longstanding interest in the complications of portal hypertension including bleeding varices, ascites, and hepatorenal syndrome. Dr. Boyer has published a number of papers in each of these areas of interest.
Wael E. Saad
Dr. Saad is a Physician of 20 years and is internationally recognized for liver disease including liver transplantation, hepatobiliary disease and portal hypertension. He has over 240 publications and over 70 book chapters and is an author of 4 books. He completed his residency at the University of Rochester, New York and his Fellowship in Vascular & Interventional Radiology at Mallinckrodt Institute of radiology, Washington University, St. Louis. He practiced Interventional Radiology at the University of Rochester and University of Virginia, where he was the program director of the Vascular & Interventional Radiology Fellowship, before coming to the University of Michigan in 2013. Dr. Saad is active in the Society of Interventional Radiology (SIR) and was awarded the SIR-Fellowship in 2010. He served as the Chairman of the SIR Standards of Practice Committee from 2011 through to 2014.
Fibrates in the Context of Cholestatic DiseasesContains 1 Component(s) Recorded On: 06/09/2016
Webinar hosted by the Cholestatic and Biliary Diseases Special Interest group on June 9, 2016.
Webinar hosted by the Cholestatic and Biliary Diseases Special Interest group on June 9, 2016.
Olivier Barbier (Moderator)
Carlo Spirli (Moderator)
Cynthia Levy, MD, FAASLD is currently a Professor of Medicine in the Division of Hepatology at the University of Miami Miller School of Medicine. Dr. Levy received her MD from Universidade Federal do Rio de Janeiro, Brazil. She completed an Internal Medicine residency at University of Miami, a Gastroenterology Fellowship at Mayo Clinic, Rochester, and a Transplant Hepatology Fellowship at University of Florida, Gainesville, having received an AASLD Fellowship Award. Dr. Levy is a member of the AASLD Practice Guidelines Committee and of the ABIM Test and Policy Committee on Transplant Hepatology. At the University of Miami, Dr. Levy is the program director for the Transplant Hepatology Fellowship program and Associate Director for the Schiff Center for Liver Diseases, where she conducts several industry-sponsored and investigator-initiated studies for cholestatic and autoimmune liver diseases.